Capitainer Participates in Global AI Project for Advanced Lung Diagnostics
Capitainer, a leading MedTech company specializing in self-sampling solutions, plays a key role in the international AIR project (Artificial Intelligence Radiology) aimed at improving the diagnostics and monitoring of lung diseases. Through Capitainer's innovative technology, patients can easily collect blood samples at home and send them for laboratory analysis, increasing healthcare accessibility for those who struggle to reach traditional healthcare facilities.
The AIR project is led by Halmstad University and brings together healthcare stakeholders from Sweden and Brazil, including InRad, the Brazilian radiological institute, Philips Healthcare, and the CERTI Foundation at EMBRAPII. The project aims to create a model for more equal and accessible healthcare globally by combining AI-based image analysis and laboratory diagnostics through self-sampling.
The project's two main areas are developing an AI-based algorithm to analyze computed tomography (CT) images and enabling easier blood sampling for patients with limited access to healthcare. As part of this project, analyses for blood markers used in lung diagnostics are being developed based on Capitainer's self-sampling technology, enabling patients to collect blood samples at home and send them to laboratories for analysis.
The algorithm provides radiologists with an effective tool to monitor disease progression over time and adapt care according to patient needs. Through AI, assessments can be standardized, reducing the subjectivity that often occurs when radiologists interpret images. This enables more accurate and reliable monitoring of the patient's condition. Capitainer's technology complements image analysis by adding biomarker data from blood samples, which can provide more comprehensive and precise diagnosis and follow-up.
"This is an exciting project that truly demonstrates Capitainer's ability to contribute to innovative healthcare solutions with global reach. Through our self-sampling technology, we can support the development of more accessible and equal healthcare, reaching more patients and making advanced diagnostics possible regardless of where patients are located. Combining our technology with AI-based image analysis can provide healthcare professionals with more comprehensive data to track and treat disease progression over time, which has the potential to improve both care precision and treatment outcomes," says Anna Ohlander, R&D Manager at Capitainer.
"By bringing together AI-based image analysis with Capitainer's self-sampling technology, we are opening up opportunities to create a new standard for how we monitor and manage lung diseases. This collaboration enables healthcare professionals to get a more objective and detailed picture of the patient's condition over time, which not only improves diagnostics but can also provide more reliable data for treatment and follow-up," says Fábio Gama, Associate Professor in Healthcare Innovation at Halmstad University.
The project receives funding from EMBRAPII, a Brazilian research institution, and the Swedish innovation agency Vinnova.
For more information, please contact:
Christopher Aulin, CEO
Phone: +46 (0)708 977577
Email: christopher.aulin@capitainer.com
About Capitainer
Capitainer AB is a Swedish MedTech company that develops and sells patient-centric solutions for self-sampling of blood, plasma, and urine. Founded in 2016, Capitainer has developed unique technologies for collecting and drying exact volumes of fluid within easy-to-use sampling cards. These cards may be sent as standard post to relevant testing laboratories, thus bypassing the need for cold chain logistics and specialised packaging. Capitainer’s products are market-leading with respect to precision and accuracy, with demonstrated equal performance to established pipetting methods. The products are applicable within several market segments, including but not limited to, clinical biomarkers, therapeutic drug monitoring, genomics, drug abuse and doping testing, and R&D and clinical studies.
Tags:
